Cart
×
CureDuchenne Welcomes New Executive Director, Vice President of Medical Affairs, and Board Members
Leading Duchenne Muscular Dystrophy Nonprofit Strengthens Leadership Team and Board Expertise
Santhera Receives Positive CHMP Opinion Recommending Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy
The Committee for Medicinal Products for Human Use (CHMP) has given a positive recommendation for AGAMREE’s approval in Europe.
Edgewise Therapeutics Announces Initiation of GRAND CANYON, a Global Pivotal Study of EDG-5506 in Becker Muscular Dystrophy (Becker)
– GRAND CANYON is the first pivotal study of an investigational therapy for Becker–– CANYON, the initial Phase 2 cohorts, is fully enrolled – BOULDER, Colo.–(BUSINESS WIRE)– Edgewise Therapeutics, Inc. (Nasdaq: […]
Austin Community Raises More Than $60,000 to Benefit CureDuchenne at Annual Ladies Luncheon
The “Afternoon in Palm Beach” Themed Event Raised Funds and Awareness for Duchenne Muscular Dystrophy AUSTIN, Texas (September 22, 2023) – Leading global nonprofit CureDuchenne held the annual Ladies Luncheon […]
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44
See Previous News Release – Initiation of Phase 1 clinical trial marks Entrada’s transition into a clinical company – – Data anticipated in the second half of 2024 – BOSTON, […]
NHL All-Star Ryan Getzlaf and CureDuchenne Raise More than $500,000 at 12th Annual Getzlaf Golf Shootout
Funds Support Global Nonprofit’s Mission of Finding a Cure for Duchenne Muscular Dystrophy NEWPORT BEACH, Calif., (September 19, 2023) – CureDuchenne, a leading global nonprofit focused on finding and funding […]
CureDuchenne Launches the CureDuchenne Caregiver Course: A Free Virtual Resource for Duchenne Muscular Dystrophy Caregivers
NEWPORT BEACH, Calif., (September 19, 2023) — CureDuchenne, a leading nonprofit organization dedicated to advancing research and improving the lives of individuals affected by Duchenne muscular dystrophy, is proud to […]
A Race Against Time: The CureDuchenne Clinic’s Remarkable Efforts Bring Life-Changing Gene Therapy to Young Boy on the Brink of Ineligibility
A Race Against Time: The CureDuchenne Clinic’s Remarkable Efforts Bring Life-Changing Gene Therapy to Young Boy on the Brink of Ineligibility.
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
FibroGen announced topline data from their Phase 3 trials of their novel antifibrotic agent, pamrevulmab, a connective tissue growth factor antibody for the treatment for ambulatory individuals with Duchenne. While pamrevlumab was generally safe and well tolerated, the study unfortunately did not meet the primary endpoint. Pamrevlumab also failed to meet its primary endpoint in non-ambulatory individuals earlier this year.